Impatto di Nirsevimab nella sua seconda stagione sulla malattia da virus respiratorio sinciziale e ammissioni non-RSV nei bambini sotto i 5 anni.

BACKGROUND: Nirsevimab was incorporated into the universal infant immunization schedule in October 2023. While its effectiveness during the first season has been described, real-world data on the second season and its impact on other respiratory virus hospitalizations are still limited, though more studies are likely to forthcoming. We aimed to evaluate the effect of nirsevimab implementation on hospital and PICU admissions for acute lower respiratory tract infections, including respiratory syncytial virus (RSV) and non-RSV etiologies, in children under 5 years of age with a specific focus on the second postintroduction season. METHODS: This retrospective study was conducted at a tertiary c